• U.S.-based communications technology brand FingerMotion is building its profits as it focuses on services for China’s world-leading, mobile-connected population
• FingerMotion recently reported its financial statement for the Q3 quarter ending Nov. 30, noting gross profits at a record $967,075
• The profits report was 56 percent higher than the same period during the previous year, driven primarily by the company’s Telecommunications Products and Services business
• FingerMotion’s Telecommunications Products and Services revenues grew 580 percent YOY despite a slowing trend for SMS services as the company shifted resources to the company’s collaboration with China Mobile in the country’s Fujian province for 5G-related SMS products

Evolving communications and big data technology company FingerMotion (NASDAQ: FNGR), is entering 2022 with record profitability and continued growth of its gross margins. “We expect this trend in gross margins to continue, and revenue should ramp as the insurtech business starts to unfold,” CEO Martin Shen stated in conjunction with the company’s announcement Jan. 18 of its financial profile for the third quarter ended Nov. 30 (https://ibn.fm/ypswa). “During the past quarter the company announced the formation of two new brands in order to provide mobile device protection in China. Beta testing is underway and could start contributing to revenue in the current quarter. The company anticipates this could represent a significant revenue stream in the next fiscal year.” FingerMotion reported its gross profit reached a new record of $967,075 during the quarter, driven by revenues of $5.9 million. That marked a 21 percent increase year-over-year in the revenue report, with the gross profit 56 percent higher YOY. The bulk of the revenue optimism came from the company’s Telecommunications Products and Services business, which grew 580 percent ($2.8 million) over the previous year’s Q3 report. The company’s Big Data analysis division, Sapientus, reported its first revenues last year and is expected to eventually be the leading revenue generator for FingerMotion as it enters the market for insurtech services. The division did not report any revenue for Q3, but the company continues to devote “considerable time … on continuing discussions with Pacific Life Re, the global life reinsurance company” that was the first company to contract with FingerMotion for big data services, Shen stated. FingerMotion is a China-focused company specializing in mobile technology services. The Asian nation contains nearly 1.5 billion mobile users and analysts at Reportlinker.com anticipate that mobile engagement in China will continue to grow in the years to come, achieving a CAGR of 44.7 percent between 2020 and 2027 for revenues of $22.4 billion by the end of the forecast period. That’s about a quarter of the analysts’ entire global forecast for the period. Shen states FingerMotion is particularly focused on the company’s collaboration with China Mobile in the country’s Fujian province. China Mobile Fujian has about 30 million or more online subscribers, which is about 70 percent of the market share in the province, according to an announcement by the company last year (https://ibn.fm/PkXvC). The mutual effort between the two companies relates to the buildup of 5G wireless network services in China, and the resources of FingerMotion SMS subsidiary JiuGe. “During the quarter we were aggressive in rolling out our collaboration with China Mobile in the Fujian province. We had to reallocate our resources into telecom which slowed the spectacular revenue growth in SMS that we had seen in the past,” Shen stated, noting that SMS texting services and multimedia MMS audio and video services have been the reason for the Telecommunications Products and Services business sector’s success. FingerMotion reported it had $1,116,448 in cash, a working capital surplus of $5,489,655 and a positive shareholders equity of $5,667,780 at the end of the quarter. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Personal knowledge management involves creating systems, adding context and making information easy to surface when needed
• The customizable, user-friendly Pluaris platform assists users with reading and analyzing textual data and so much more
• Nowigence is focused on simplifying the challenges of learning

The idea of personal knowledge management (“PKM”) systems is gaining traction, with a growing number of individuals and companies recognizing the importance of managing information more efficiently for more successful outcomes. Seeing an opportunity to provide critical support in this quest for knowledge management, Nowigence Inc. (NOWG) has created Pluaris(TM), a cloud-based app that automates reading and analysis of textual data so users can learn more in less time while uncovering hidden insights and staying on top of the information they need to know. “Personal knowledge management is the concept of creating a process or system for collecting and storing information for future use,” explains a recent Search Engine Journal article (https://ibn.fm/4239C). “It’s different from how most of us currently collect digital information, which could more accurately be described as hoarding — accumulating hundreds of bookmarked articles, highlighted book passages, and jotted down statistics. “Digital hoarding doesn’t help you use the information you’re collecting; it makes it harder,” the article continued. “Personal knowledge management, on the other hand, involves creating systems, adding your own context, and making information easy to surface when you need to reference it.” That’s just the beginning of what Nowigence’s Pluaris enables users to do. The customizable, user-friendly platform assists users with reading and analysis of textual data — and so much more (https://ibn.fm/YUxHC). Using artificial intelligence and machine learning, Pluaris automatically analyzes the content it reads by extracting summary points and segregating them as key highlights and the reasons for action, called drivers. These drivers then lay the foundation for cause-and-effect analysis designed to provide readers with key information to help in data gathering and problem solving. Pluaris also labels answers to the most frequently asked questions about topics, such as who, what, where, when, why, how, and how much. It identifies categories and discovers connections. Of course, being able to explore and identify information when it is needed is crucial. Pluaris includes Ask Me, a Google-like search feature, that finds and retrieves information. However, unlike Google, Pluaris is able to search through a person’s internal knowledge base in drives, instant messaging, enterprise tools or other data systems when they are connected with the platform. Nowigence is focused on simplifying the challenges of learning. By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to Nowigence are available in the company’s newsroom at https://ibn.fm/NOW

• Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS
• Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes
• NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor
• Company recently completed initial shipment to UK licensee

While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech market with sugarBEAT(R) – a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help diabetes patients manage glucose levels. Diabetes is a significant concern in the United States, according to a report released by the Center for Disease Control (“CDC”) that provides statistics across ethnicities, ages, education levels, and regions (https://ibn.fm/Ch1HI). According to the report, 34.2 million Americans – roughly 10 percent – have diabetes, and approximately one in three have pre-diabetes. “CDC is working to reverse the epidemic by helping to identify people with pre-diabetes, prevent type 2 diabetes and diabetes complications, and improve the health of all people with diabetes,” reads the report. “Through the National DPP’s evidence-based, affordable lifestyle change program, adults with pre-diabetes learn to make healthy changes that can cut their risk of type 2 diabetes by as much as 58% (71% for those over 60 years).” Controlling insulin is an essential part of the lifestyle changes required to manage and prevent diabetes, according to the US National Institute of Health (“NIH”) (https://ibn.fm/z5jJe). Accordingly, the medtech industry has grown considerably to meet the demand for insulin-monitoring equipment such as insulin pumps and CGM devices. While most businesses faced severe business restraints in 2021, the diabetes tech space had an eventful year with highlights that included climbing user numbers, expansion of coverage for glucose monitoring devices by the Centers for Medicare & Medicaid Services (“CMS”), and bullish analyst projections that forecast increased adoption of diabetes tech devices in 2022 and beyond. NMRD is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible, and affordable CGM device. With actionable insights from real-time glucose monitoring, sugarBEAT(R) is designed to help diabetic and pre-diabetic people prevent, manage, and reverse diabetes symptoms. As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT(R) devices to MySugarWatch Limited, its UK licensee. MySugarWatch Limited intends to market sugarBEAT(R) via a subscription-based diabetes coaching and management service that targets over 4.9 million diabetics and 13.6 million people with an increased risk of contracting Type 2 diabetes in the UK (https://ibn.fm/OdNBO). “This initial shipment of sugarBEAT(R) CGM devices to our UK licensee allows the Company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” said Nemaura CEO, Dr. Faz Chowdhury. “Starting in the UK, patients with Type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence, and outcome.” Founded in 2011, NMRD initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved into the wearables space at the intersection of global diabetes, pre-diabetes, and weight loss device markets. With diabetes and obesity on the rise, NMRD is dedicated to addressing the growing need for flexible, affordable glucose monitoring solutions that help prevent, manage, and reverse diabetes and pre-diabetic conditions. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment
• The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1
• All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year
• Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health

In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”), noted that Lexaria would continue to see significant milestones in utilizing DehydraTECH-CBD, focusing on heart disease and hypertension. “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” noted Mr. Bunka. “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added (https://ibn.fm/0HA7M). It received independent review board approval in what marks a significant milestone for its 2022 R&D program. The approval comes in less than two months after Lexaria announced that it was readying the study protocols for its HYPER-H21-4 study, its fourth recent human clinical study, and its most ambitious one yet (https://ibn.fm/aurm0). The approval sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. HOR-A22-1 study, scheduled to start in April 2022, will evaluate DehydraTECH’s ability to enhance the delivery characteristics of estrogen. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia. Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively, in a move that is intended to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health. All the R&D for the 2022 calendar year is fully funded, having raised approximately $15 million in funding over the 2021 calendar year. Lexaria is confident that data from the studies will support the company’s plans to enter regulatory pathways, which, it anticipates, will result in the regulatory approval to use DehydraTECH-CBD for the treatment of hypertension and possibly other types of cardiovascular disease. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SRAX’s performance goes from strength to strength; company announced revenue guidance expecting revenues of $11.5 million for the first quarter and full-year revenues of $46M – $48M.
• Company’s SaaS platform Sequire expected to continue to drive growth and remain instrumental to performance.
• As go-to data provider for investors and public companies, SRAX stays committed to innovating on product, sales, and marketing, which all translates into increased revenue.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced revenue guidance for 2022, anticipating another strong period ahead. The company expects revenues of $11.5 million for the first quarter, a 111% increase over Q1 2021 revenue. The full-year revenues are expected to be $46M – $48M, an increase of 46% – 52% over 2021 unaudited revenue of approximately $31.5M. In addition, the company announced that the Q4 2021 booking meets expectations (https://ibn.fm/PJKY8). With solutions built to bring clarity and make the digital space more transparent, SRAX aims to deliver unbiased data and reveal analytics for companies to manage ROI from investor relations programs and corporate communication firms. The company’s growth remains closely linked to Sequire, its SaaS platform. Last year the platform grew both in subscribers and functionality, resulting in considerable revenue growth and customer renewals. This year Sequire has a number of significant releases that will continue to enhance the platform’s value. Sequire’s success is driven by its focus on delivering solutions that solve important pain points for public companies. To stay competitive in today’s environment, companies need to better communicate with their shareholders and the broader investment community. As a data analytics platform designed for public companies to track essential data, SRAX provides unique opportunities for investors and public companies to connect and communicate through its Sequire SaaS platform. Sequire provides users with data that help them understand market activity and develop insights to engage their investor base. With this platform, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. SRAX has also expanded its model to include additional value-added services from the investor relations space, such as their preeminent industry conferences. The company owns LD Micro, a respected conference provider targeted at small and micro-cap markets. “Our team did excellent work in 2021, meeting and exceeding our guidance. The nature of our annual contracts provides us exceptional visibility into revenue,” said Christopher Miglino, Founder and CEO of SRAX. “We are projecting that we will have our largest quarter ever in Q1 of 2022. With an acceleration in sales at the end of Q4, we are very comfortable in providing a full-year, 2022 guidance of $46-$48M,” added Miglino. SRAX has seen its financial performance go from strength to strength over the past year, with recently reported results revealing exceptional revenue growth. Its remarkable performance and growth trajectory appear to have contributed to the increased investors’ interest, with several hedge funds and other institutional players adding to their stakes in the company (https://ibn.fm/J6IAL). For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Over 466 million people current suffer from disabling hearing loss with a further 1.1 billion people at risk of suffering hearing damage
• Elevated device cost, poor after-sales service, and a lack of access to proper healthcare have led to only 14% of the 48 million American with hearing loss to currently use hearing aid devices
• InnerScope Hearing Technologies has sought to address this issue with its affordable direct-to-consumer sales model
• InnerScope CEO, Matthew Moore presented at the Emerging Growth Conference on January 5th, updating shareholders and investors on the company’s latest operational highlights

As of March 2019, the World Health Organization (“WHO”) estimated that disabling hearing loss affected around 466 million people across the globe, out of whom 34 million were children. Moreover, the WHO forecast that up to 1.1 billion people between the ages of 12 to 35 years globally were subject to hearing loss risk, largely due to constant noise exposure (https://ibn.fm/ftcaw). InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), has long sought to become a leader in the direct-to-consumer hearing aid market, with the goal in mind to provide affordable hearing to the tens of millions of Americans suffering from hearing loss today. Elevated device costs, problems associated with devices such as post-purchase services, battery problems, and maintenance issues, along with poor access to adequate healthcare, are all factors that have historically contributed towards restricting the growth of the global hearing aid market. In fact, a recent White House Fact Sheet revealed that the elevated cost of hearing aids had led to only 14% of the approximately 48 million Americans with hearing loss using them (https://ibn.fm/pEwQI). In addition, a heavily concentrated marketplace – with the four largest hearing aid manufacturers controlling upwards of 84% of the market – has also contributed to the elevated pricing for the devices. Nonetheless, the global hearing aid market is estimated to display a strong underlying growth trend over the coming years, with a forecast 6.6% CAGR between 2021-2028. Through its dedicated online portal, www.iHeardirect.com, InnerScope has looked to provide consumers with affordable, Bluetooth app-controlled, self-adjusting hearing technology in a prompt and affordable manner. The company’s HearIQ App for iPhone and Android has been designed to include a free self-check hearing test, providing billions of people worldwide with the means to detect and self-diagnose early-onset hearing loss. Meanwhile, the company’s proprietary hearing technology provides customers with the ability to personalize each hearing device to their hearing needs in under 10 minutes. InnerScope Hearing Technologies recently acquired HearingAssist, a long-established leader in the direct-to-consumer hearing aid market and Walmart’s largest hearing aid supplier, for a gross consideration of $10 million, with the express intent to create a “powerful disruptive company in the global hearing device market.” At the time of acquisition, Matthew Moore, President and CEO of InnerScope, stated, “Today is a tremendous milestone for InnerScope. I’m delighted to welcome the HearingAssist team, who share our passion for providing convenient and affordable hearing products for the tens of millions of Americans who suffer from hearing loss. The HearingAssist acquisition is another meaningful step in advancing our strategy to grow as a leader and innovator in the direct-to-consumer hearing aid market.” Separately, InnerScope Hearing has revealed that Matthew Moore was invited to present at the Emerging Growth Conference, a live interactive online event that took place on Wednesday 5^th January, which allowed InnerScope’s existing shareholders and the investment community to interact with InnerScope’s CEO in real-time. Interested investors. You can watch Moore presentation by clicking on the link: https://www.youtube.com/watch?v=QuAndXZLbMk Moore’s presentation highlighted InnerScope’s two recent direct-to-consumer hearing aid company acquisitions with iHear Medical Inc., its 40+ patents, and its iHearTest, the only FDA-cleared, in-home hearing test on the market and sold at CVS Pharmacy’s; and HearAssist II LLC., Walmart’s largest hearing aid supplier. In addition, Moore discussed InnerScope’s 2022 growth trajectory with these pivotal acquisitions and a key partnership with Atlazo Inc., a leader in intelligent semiconductor solutions, to develop new types of unprecedented artificial intelligence hearing products. For more information, visit the company’s website at www.INND.com and the company’s e-commerce websites www.iHeardirect.com and www.HearingAssist.com NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• President and CTO Dean Rositano was invited to be a new member of the prestigious Rolling Stone Culture Council – an invitation-only network of leaders who are on the cutting edge of culture, community, and the Rolling Stone brand
• Artist Republik will join Fan Pass Live as a Friendable Company, increasing the number of artists on the platform
• CEO and Co-Founder Robert Rositano Jr. explained that one of the company’s main goals has always been to test multiple entry points to gain exposure in the music industry for artists and fans alike

Mobile technology and marketing company Friendable (OTC: FDBL) has achieved several important milestones throughout 2021 and has big things planned for the new year as well, focusing mostly on further scaling its Fan Pass Live artist streaming platform offering and expanding its industry relationships. Taking one step closer to achieving the latter, the company announced that President and CTO Dean Rositano was invited to be a part of the prestigious Rolling Stone Culture Council (https://ibn.fm/lbXDe). The Council is an invitation-only network of leaders who are on the cutting edge of culture, community, and all it takes to be associated with the Rolling Stone brand. Mr. Rositano was invited to be a part of this community because of his contributions to the music, entertainment, and technological industries. This includes his successful development of automated solutions, services, and technology that enable artists to take true ownership and control over their music and careers. Mr. Rositano has the honor of joining senior leaders from across North America and Europe in music, art, technology, fashion, gaming, media, sports, and entertainment. “Mr. Dean Rositano is an inspiring leader, and we value the knowledge and experience he brings to this community,” Council Co-Founder Scott Gerber said. “The Council brings together members with the right mix of expertise, passion, and energy to do great things. Individuals, businesses, and industries all benefit from the learning and collaboration happening inside.” The announcement follows another major milestone that was recently announced by the company: the closing of the acquisition of Artist Republik, a reputable music distribution company (https://ibn.fm/4fIiX). Following the acquisition transaction completion, Artist Republik is now officially a Friendable Inc. company alongside Fan Pass Live. The new acquisition will add approximately 100,000 artists to the platform and triple the technology deck. The acquisition comes after approximately one year of talks and negotiations between the two companies to seal a partnership, as Artist Republik was moving toward the development of livestream services and Fan Pass was moving toward its own music distribution offering. According to CEO Robert Rositano Jr., Friendable was also able to retain the Artist Republik CEO and CTO as initial consultants after the acquisition, assisting with integration efforts and expanding the service offering. Artists will also receive more autonomy and freedom over their music, ticketed streams, blog/social promotions, exclusive merchandise development, sales, and more. All of this is available to artists without the requirement to give up their musical rights. Friendable also provided the public and its shareholders with a summary of milestones for 2021 and the plans made for 2022. The company has come a long way since its flagship offering, Fan Pass Live artist streaming platform, was released in July 2020, with 16 artists performing live on the platform at the time of the launch. In February 2021, the platform set a record for artist signups, reaching over 350% growth compared to the previous month, including 100% growth in livestream events. By July 2021, when an updated version with new features and options was released, the platform had surpassed 5,000 artist members. In a company press release detailing achievements and strategies, Rositano Jr. thanked all artists members, fans, partners, supporters, team, and shareholders (https://ibn.fm/ysLxn). “We would not be here without each and every one of you pulling for us, and the progress certainly shows we are on the correct path,” he said. Rositano Jr. also said new service offerings will be announced soon as the company expands into various channels of music distribution, working towards the same goal of scaling revenues, number of artists and fan subscribers on the platform. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

MSLs are critical in ensuring that products are used efficiently throughout their lifecycle. They serve as scientific peers and resources within the medical community, and provide valuable expertise to internal colleagues. MSLs, like the rest of the life science industry, must quickly adapt to the introduction of new technological platforms and rethink their workload in the post-COVID era. DGE will cordially welcome many professionals to attend the 2nd annual Next-Gen MSL Excellence Symposium, the only industry event dedicated to conquering the daily problems that this critical group faces while achieving career milestones and adjusting to new technology! This symposium is the only virtual industry event dedicated to the work problems encountered by MSLs, emphasizing the relevance of their role in drug and device development as well as adjusting to new technologies in the post-COVID era. Why Should You Attend It?

• Strategies for outlining and achieving professional objectives
• A guide for developing the leadership qualities to advance in your career path
• Key methods for enhancing KOL engagements by honing communication and soft skills.
• Techniques for collaborating well with cross-functional teams and participating in strategic planning
• Innovative ways to use artificial intelligence and social media to gather information and impact medical policy
• Learning and networking with field medical professionals and industry leaders in an interactive online platform

DGE’s 2nd Next-Gen MSL Excellence Symposium will provide a dynamic platform for medical industry KOLs and decision-makers to share their perspectives and discuss the role of MSLs in the changing landscape. They will also provide valuable tips and techniques for building a successful career and demonstrating the value of their skills to the company. This conference is also a fantastic chance for talented individuals interested in pursuing a successful MSL career. Medical Affairs personnel will contact teams that conduct similar duties in order to gain new and expanded ideas and roles. For more information, visit https://ibn.fm/aHMOd.

• Hollywall owns the rights to and music recordings of more than 17,500 songs, in addition to the rights to 29 video games and a film
• As of December 2019, the company’s music library was valued at $146 million
• The music industry has witnessed an upsurge in music catalog acquisitions by investment and management firms and leading music companies
• Hollywall is led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments

The 2010s saw an upsurge in music catalog acquisitions, a trend that only accelerated into the 2020s. Describing this “catalog acquisition frenzy,” a January 2021 Rolling Stone Magazine article observed that even investment and management firms and Wall Street companies had entered into the music business by buying rights to famous musicians’ creative works (https://ibn.fm/UCEZK). “Right now, the gorillas in this jungle include Larry Mestel’s Primary Wave and Merck Mercuriadis’s Hipgnosis Songs Fund, two investment and management firms: in 2021 alone, the latter company acquired copyrights and/or income streams from Neil Young, Lindsey Buckingham of Fleetwood Mac, Shakira, and Jimmy Iovine,” reads the article. “This isn’t the first time in recent memory that Wall Street mammoths have gotten involved in the inner workings of the music business,” the article continues. “In 2016, BlackRock (a company with $7.8 trillion in assets under management) led a $300 million investment into Primary Wave – money that was subsequently spent on legendary music catalogs like Bob Marley’s.” Leading music companies such as Warner Music Group and Universal Music Group have also splurged tens of millions of dollars on music catalogs. The logic behind such acquisitions is simple. Firstly, master recordings earn revenue through various avenues, namely sampling, streaming and purchases/downloads, public broadcast, and use in television, film, and commercials. Secondly and according to a 2020 Variety Magazine article, “Publishing assets are currently running at multiples well over 12 with master rights slightly lower but increasing in value… In five to 10 years, it might be 20x – the value continues to rise” (https://ibn.fm/OBLpT). Notably, the market multiple analysis is a valuation approach that applies an EBITDA multiple or Net Publisher’s Share (“NPS”)/Net Label’s Share (“NLS”) multiple based on recent precedent acquisitions. It is used to derive a catalog’s implied market value (https://ibn.fm/Mjfe2). The increasing interest in music catalogs and their projected rise in value bodes well for Hollywall Entertainment (OTC: HWAL), an entertainment, media, infrastructure, telecommunication, technology, and broadcasting company that operates through various subsidiaries. The company, which serves some of the finest creators, writers, developers, and music artisans of our time by offering a business solution and distribution platform that maximizes a global audience reach, wholly owns an extensive music and entertainment library. Hollywall’s asset portfolio includes copyrights, legal rights, trademarks, and master recordings of over 17,500 songs, one of the largest master recording libraries globally. This library features hit songs from the likes of Michael Jackson, Elvis Presley, The Jacksons 5, Marvin Gaye, Dolly Parton, Frank Sinatra, The Who, Bob Marley, Quincy Jones, James Taylor, and more. In addition, HWAL owns the source code, rights, and trademarks of 29 video games and the rights to a film titled ‘The Elvis I Knew.’ With a fair value of about $146 million as of December 31, 2019, according to an intangible asset valuation prepared by Sun Business Valuation and available on the HWAL’s website (https://ibn.fm/3SdFe), Hollywall’s master recordings are only bound to increase in value as time progresses, positioning HWAL for growth well into the future. Led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments, Hollywall is favorably poised as one of the entertainment industry’s most exciting companies. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms
• The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation on psychedelics. Delic announced that the Company’s Co-founder and Chief Executive Officer, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference, held in an entirely virtual format from January 10-13, 2022. In addition to carrying out one-on-one meetings throughout the course of the conference, Mr. Stang made a corporate presentation on Delic Corp’s expansion strategy and overall industry outlook for the general public. H.C. Wainwright & Co., a full-service investment bank dedicated to providing investment banking, equity research, sales and trading, as well corporate access and strategic advisory services, celebrated 150 years of service in 2018. The firm has gained a well-deserved reputation for its innovative conference line-up over the years, having recently hosted events on topics as varied and diverse as psychedelics, mining, precision oncology, hepatitis B, ophthalmology, cryptocurrencies, blockchain technology and applications, and many more. The H.C. Wainwright Bioconnect Conference, hosted by former FDA commissioner Dr Scott Gottlieb, has sought to bring together a carefully curated collection of cutting-edge biopharmaceutical firms alongside institutional investors, private equity firms, venture capitalists, and industry executives. According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30% of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/Bu2g4). With the sector on the cusp of broad-based legalization, the psychedelic wellness market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/jFEPL). Delic has sought to capitalize on the sector’s growth as well as rising demand for psychedelic products and services through the expansion of its proprietary Ketamine Wellness Centers (“KWC”), the largest chain of psychedelic wellness clinics in the country, with 15 more clinics opening in the next 18 months. Delic has also looked to expand its footprint within the sector through its other related businesses, which include Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the world’s largest psychedelic wellness event; as well as media platforms, Reality Sandwich and Delic Radio. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF